Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esculin and Digitalis Glycosides Eye Drops for Presbyopia
NCT07151612Phase 4Completed
- Sponsor
- Shanxi Eye Hospital
- Start
- Sep 2025
- Primary completion
- Oct 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of esculin in presbyopia (2 arms), sponsored by Shanxi Eye Hospital. Primary endpoint: Distance Corrected Near Visual Acuity. Started Sep 2025; status: completed.
02
Drugs
esculin
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT07151612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07151612.